Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

fowlpox-NY-ESO-1 vaccine

Known as: rF-NY-ESO-1 
A cancer vaccine consisting of a recombinant fowlpox virus vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, an… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
NY‐ESO‐1 specific antibody and cellular responses in melanoma patients primed with NY‐ESO‐1 protein in ISCOMATRIX and boosted with recombinant NY‐ESO‐1 fowlpox virus
Vaccination strategies based on repeated injections of NY‐ESO‐1 protein formulated in ISCOMATRIX particles (NY‐ESO‐1 ISCOMATRIX… Expand
2013
2013
NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma.
During cancer progression, malignant cells may evade immunosurveillance. However, evidence for immunological escape in humans is… Expand
Highly Cited
2012
Highly Cited
2012
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients
Recombinant poxviruses (vaccinia and fowlpox) expressing tumor-associated antigens are currently being evaluated in clinical… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2004
2004
LUD00-014: Phase I Study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers
Study design Eligible patients (pts) for the first part of the study were HLA-A2+ with advanced NY-ESO-1/LAGE+ tumors assessed by… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE